Camila Bragança Xavier, M.D.

Peer-Reviewed Articles

1. Braganca Xavier C, Andersen CR, Lim J, Slade JH, Bean SA, Kang L, Le H, Tsimberidou AM, Naing A, Hong DS, Dumbrava EE, Rodon Ahnert J, Pohlmann PR, Piha-Paul SA, Champiat S, Yap TA, Tang TY, Meric-Bernstam F, Fu S. Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase 1 Unit. Cancer Res Commun, 2025. e-Pub 2025. PMID: 40862547.
2. Nardo M, Braganca Xavier C, Stephen B, How JA, Moyers J, Subbiah V, Hong DS, Naing A. Pembrolizumab in Patients with Advanced Miscellaneous Rare Cancers: Results from a Phase 2 Basket Trial. J Immunother Precis Oncol 8(2):143-151, 2025. e-Pub 2025. PMID: 40212844.
3. Braganca Xavier C, Guardia GDA, Alves JPB, Lopes CDH, Awni BM, Campos EF, Jardim DL, Galante PAF. Identifying predictors of overall survival among patients with TMB-low metastatic cancer treated with immune checkpoint inhibitors. Oncologist 30(4), 2025. e-Pub 2025. PMID: 40285678.
4. Araujo ML, Tozzi VAC, Carvalho de Souza M, Gomes LBM, de Medeiros MFB, Xavier CB, Wu TC, Machado MAC, Costa FP. Recurrent neurogenic shock as a rare postoperative complication associated with pancreaticoduodenectomy with mesopancreas excision in elderly patient: a case report. Gland Surg 13(11):2206-2211, 2024. e-Pub 2024. PMID: 39678426.
5. Nardo M, Xavier CB, Franke F. Phase 1 Clinical Trials: Challenges and Opportunities in Latin America. J Immunother Precis Oncol 7(3):168-170, 2024. e-Pub 2024. PMID: 39219993.
6. Mendes Gomes LB, Lazari Sandoval R, Braganca Xavier C, Strava Correa T, Koga Matuda RM, Silva de Souza Z, Cernaglia Aureliano de Lima LG, Petaccia de Macedo M, Marino Carvalho F, Assad Suzuki D. Primary Peritoneal Carcinosarcoma in a Breast Cancer Patient Harboring a Germline BRCA2 Pathogenic Variant: Case Report. Case Rep Oncol 17(1):1-9, 2024. e-Pub 2024. PMID: 38179550.
7. de Souza ZS, Xavier CB, Gomes LBM, de Medeiros MFB, de Sousa MC, Pereira AAL, Marin JFG, Buchpiguel CA, Costa FP. Survival and Response Outcomes for Gastrointestinal Neuroendocrine Tumor (GEP-NETs) Patients Treated with Lutetium-177-DOTATATE in a Brazilian Reference Center: A Six-Year Follow-Up Experience. Cancers (Basel) 15(18), 2023. e-Pub 2023. PMID: 37760475.
8. Xavier CB, Link R, Abreu L, Bettoni F, Marson F, Galante PAF, Masotti C, Amano MT, de Molla V, Camargo AA, Asprino PF, Sabbaga J. Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board. Oncologist 28(7):624-627, 2023. e-Pub 2023. PMID: 37159554.
9. Lima NF Jr, Sampaio LAF, Xavier CB, Mattedi RL, Queiroz MA, Nahas WC, Jardim DL. Complete Response to Sequential Human Epidermal Growth Factor Receptor 2-Targeted Strategies in a Heavily Pretreated Patient With Human Epidermal Growth Factor Receptor 2-Amplified Metastatic Bladder Cancer. JCO Precis Oncol 7:e2200414, 2023. e-Pub 2023. PMID: 36623240.
10. Xavier CB, Lopes CDH, Awni BM, Campos EF, Alves JPB, Camargo AA, Guardia GDA, Galante PAF, Jardim DL. Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors. Cancers (Basel) 14(21), 2022. e-Pub 2022. PMID: 36358851.
11. Xavier CB, Lopes CDH, Harada G, Peres EDB, Katz A, Jardim DL. Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis. Transl Oncol 19:101383, 2022. e-Pub 2022. PMID: 35248919.
12. Camila B. Xavier, Felipe S.N.A. Canedo, Fabiola A.S. Lima, Raissa R. Melo, Luiz Guilherme C.A. Lima, Jose Flavio G. Marin, Ciro E. Souza, Olavo Feher. Complete response to alectinib following crizotinib in an ALK-positive inflammatory myofibroblastic tumor with CNS involvement. Current Problems in Cancer: Case Reports, 2021. e-Pub 2021.
13. Vieira AC, Xavier CB, Vieira TD, Carvalho FM, Scaranti M, Munhoz RR, Carvalho JP. CIC-DUX4 rearranged uterine cervix round-cell sarcoma exhibiting near-complete pathologic response following radiation and neoadjuvant chemotherapy: A case report. Gynecol Oncol Rep 36:100745, 2021. e-Pub 2021. PMID: 33850994.
14. Xavier CB, Marchetti KR, Castria TB, Jardim DLF, Fernandes GS. Trametinib and Hydroxychloroquine (HCQ) Combination Treatment in KRAS-Mutated Advanced Pancreatic Adenocarcinoma: Detailed Description of Two Cases. J Gastrointest Cancer 52(1):374-380, 2021. e-Pub 2021. PMID: 33225411.

Review Articles

1. Villarreal-Garza C, Aranda-Gutierrez A, Gonzalez-Sanchez DG, Braganca-Xavier C, Negrete-Tobar G, Chavarri-Guerra Y, Mohar A, Barrios C, Coutinho A, Jamal A, Hricak H, Loehrer P, Moraes FY, Murillo R. National cancer control plans in Latin America and the Caribbean: challenges and future directions. Lancet Oncol 26(6):e320-e330, 2025. e-Pub 2025. PMID: 40449506.
2. Lopes CDH, Braganca Xavier C, Torrado C, Veneziani AC, Megid TBC. A Comprehensive Exploration of Agents Targeting Tumor Microenvironment: Challenges and Future Perspectives. J Immunother Precis Oncol 7(4):283-299, 2024. e-Pub 2024. PMID: 39524466.

Other Articles

1. Felicio de Campos E, Xavier CB, Queiroz MM, Firmino Lima Junior N, Ilario EN, Coelho RF, Nahas WC, Bastos DA, Fontes Jardim DL Cardiovascular and Thromboembolic Events in Patients With Localized Prostate Cancer Receiving Intensified Neoadjuvant Androgen Deprivation: A Systematic Review and Meta-Analysis. Clin Genitourin Cancer 22(3):102088, 2024. PMID: 38718699.
2. Mauricio Fernando Silva Almeida Ribeiro, Camila Braganca Xavier, Allan Andresson Lima Pereira, Mariana Scaranti, Luiza Dib Batista Bugiato Faria, Tatiana Strava Correa, Marina Sahade, David Queiroz Borges Muniz, Olavo Feher, Gustavo dos Santos Fernandes, Artur Katz, Rodrigo Ramella Munhoz The addition of PD-1/PD-L1 axis blockade to BRAF and MEK inhibition for advanced melanoma patients harboring BRAF mutations: a systematic review and meta-analysis. Brazilian Journal of Oncology, 2022.
3. Braganca Xavier, C, Fu, S A Phase I Study of Cabozantinib and Pamiparib to Evaluate Triple Inhibition pf PARP, VEGFR and c-MET in advanced Homologous Recombination Deficient Malignancies.
4. Fu S, Braganca Xavier, C, Keyomarsi K, Wang Y, Ferry-Galow K, Wilsker D, Paradiso F, Kushnarev V, Yuan Y, Previs RA, Elias AD, Carvajal R, George TJ, Yao S, Yuan Y, Dumbrava EI, Piha-Paul SA, Tsimberidou AM, Ahnert JR, Westin S, Meric-Bernstam AF Biomarker analyses of WEE1 inhibition in patients with refractory CCNE1 amplified solid tumors.
5. Xavier CB, Massaro M, Paradiso F, Kotlov N, Hensley M, Hong DS, Ahnert JR Co-incidence of KRAS mutations and MTAP gene alterations in pancreatic cancer: genomic landscape and potential implications to clinical practice.
6. Braganca Xavier, C, Pant, S, Haymaker, C A Phase I/II Study of MRx0518 In Combination with Pembrolizumab In Patients with Advanced Malignancies who Have Progressed On PD-1/PD-L1 Inhibitors.
7. Xavier CB, Fu S, Hong DS, Piha-Paul SA, Naing A, Ahnert JR, Yap TA, Karp DD, Dumbrava EE, Heymach J, Ajani JA, Cartwright C, Beck J, Andersen CR, Kahle M, Vining DJ, Ross JS, Chao CY, Berry DA, Meric-Bernstam F, Tsimberidou AM Results of IMPACT2, a Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer at MD Anderson Cancer Center.
8. Camila B Xavier, Mohamed A Gouda, Apostolia M. Tsimberidou Prolonged Response to Dual Immune Checkpoint Blockade in Patients with Advanced Solid Tumors: A Case Series.
9. Uzunparmak B, Su F, Johnson A, Shaw KR, Kong EK, Korkut A, Xavier CB, Yuan Y, Fowler N, Paradiso F, Kontselidze L, Butusova A, Bagaev A, Ileana-Dumbrava EE, Rodon-Ahnert J, Hong DS, Yap TA, Naing A, Piha-Paul SA, Ferrarotto R, Iorgulescu B, Kulkarni S, Patel KP, Meric-Bernstam F Comprehensive Genomic and Transcriptomic Analysis to Guide Therapy for Patients with Metastatic Solid Tumors.
10. Camila Braganca Xavier, Carlos Torrado Martin, Timothy A. Yap Development of the Poly (ADP-Ribose) Polymerase (PARP) inhibitor talazoparib and associated companion diagnostics in advanced breast cancer.
11. Carlos Torrado, Camila Braganca Xavier, Harold Tan, Natalie Ngoi, Timothy A. Yap Drugging the DNA damage response (DDR) in the clinic: going beyond the approved PARP inhibitors.
12. Gerald Falchook, Camila Braganca Xavier, David Van Veenhuyzen, Jyoti Malhotra, Saeed Sadeghi, Arash Rezazadeh Kalebasty, Lauren Wood, Faisal Rahman, Elizabeth Li, Yvonne Pak, Alexander I. Spira, David Sommerhalder, Ignacio Garrido-Laguna, David S. Hong A Phase 1/1B First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients with Advanced Solid Tumors.

Abstracts

1. Camila Braganca Xavier, Lei Kang, Hung Le, Michael Kahle, Apostolia Maria Tsimberidou, Aung Naing, Ecaterina Elena Dumbrava, Jordi Rodon Ahnert, Paula R. Pohlmann, Sarina A. Piha-Paul, Siqing Fu, Stephane Champiat, Timothy A. Yap, Tin-Yun Tang, Scott Kopetz, Funda Meric-Bernstam, David S. Hong. Colorectal cancer with gene fusions – navigating the genomic landscape and treatment selection in a phase I unit. 2025 ASCO Annual Meeting, 2025. e-Pub 2025.
2. Camila Braganca Xavier, Clark Andersen, JoAnn T. Lim, Julian H. Slade, Stacie A. Bean, Lei Kang, Hung Le, Apostolia Tsimberidou, Aung Naing, David Hong, Ecaterina Dumbrava, Jordi Rodon, Paula Pohlmann, Sarina Piha-Paul, Stephane Champiat, Timothy A. Yap, Tin-Yun Tang, Funda Meric-Bernstam, Siqing Fu. Modulating treatment outcomes of patients with solid tumors in immunotherapy trials: a drug interaction analysis from a phase I unit. AACR 2025 Annual Meeting, 2025. e-Pub 2025.
3. Mohamed A. Gouda, Camila B. Xavier, Carlos Torrado, Pooja A. Shah, Kunal Rai, Natalie Vokes, Omar Alhalabi, Mark T. Bedford, Jianjun Gao, Nazanin K. Majd, Jenny Li, Milind Javle, Funda Meric-Bernstam, Jordi Rodon. Pan-cancer prevalence of unusual MTAP alterations: data from the AACR GENIE database. AACR 2025 Annual Meeting, 2025. e-Pub 2025.
4. Olavo Feher, Caroline Chaul, Camila Braganca Xavier, Micelange Carvalho de Sousa, Leonardo Testagrossa, Maria Fernanda Barbosa de Medeiros, Luana Alencar Fernandes Sampaio, Rene Gansl, Rogerio Tuma, Sibele Meireles, Tatiana Zanesco, Antonio Iemma, Tiago Costa, Bertram Wiedenmann, Jack Tuszynski, Frederico Perego Costa. Systemic delivery of low energy radiofrequency electromagnetic fields for the treatment of patients with primary brain tumors. Society for Neuro-Oncology (SNO) Annual Meeting, 2024. e-Pub 2024.
5. C.B. Xavier, G. Guardia, J.P. Alves, C.D.H. Lopes, B. Awni, E.F. de Campos, A.A. Camargo, D.L.F. Jardim, P. Galante. Identifying predictors of Overall Survival among TMB-low Cancer Patients Treated with Immune Checkpoint Inhibitors. 2023 ESMO congress, 2023. e-Pub 2023.
6. Eduardo Felicio Campos, Camila Braganca Xavier, Marcello Moro Queiroz, Nildevande Firmino Lima, Denis L. Jardim, Diogo Assed Bastos, Eder Nisi Ilario, Rafael Ferreira Coelho, William Carlos Nahas. Cardiovascular and thromboembolic events associated with intense neoadjuvant androgen deprivation therapy followed by prostatectomy in patients with localized prostate cancer: A meta-analysis of clinical trials. 2023 ASCO Genitourinary Cancers Symposium, 2023. e-Pub 2023.
7. Zenaide Silva Souza, Camila Braganca Xavier, Luciana Beatriz Mendes Gomes Siqueira, Maria Fernanda Barbosa de Medeiros, Micelange Carvalho de Souza, Maria Dirlei de Souza Begnami, Allan Andresson Lima Pereira, José Flávio Gomes Marin, Carlos Alberto Buchpiguel, Frederico Costa. Survival outcomes for patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with lutetium-177-dotatate (Lu-177) in a Brazilian reference center: A six-year follow-up experience. 2023 ASCO Gastrointestinal Cancers Symposium, 2023. e-Pub 2023.
8. Camila Bragança Xavier, Gabriela Guardia, Carlos Diego Holanda Lopes, Beatriz Mendes Awni, Eduardo Felicio Campos, Joao Pedro Alves, Anamaria Aranha Camargo, Pedro Alexandre Favoretto Galante, Denis L. Jardim. Association between tumor mutational burden (TMB) and mutational profile and its effect on overall survival: A post hoc analysis of patients with TMB-high and TMB-low metastatic cancer treated with immune checkpoint inhibitors (ICI). 2022 ASCO Annual Meeting, 2022. e-Pub 2022.
9. C.B. Xavier, C.D.H. Lopes, B.M. Awni, E.F. de Campos, J.P.D.B. Alves, D.L.F. Jardim. Interplay between mutational profile and TMB on overall survival: A post hoc analysis of 1,662 metastatic patients treated with immune checkpoint inhibitors. 2021 ESMO Immuno-oncology conference, 2021. e-Pub 2021.
10. Camila Bragança Xavier, Carlos Diego Holanda Lopes, Guilherme Harada, Artur Katz, Denis Leonardo Fontes Jardim. Cardiovascular toxicity incidence following immune checkpoint inhibitors in randomized clinical trials: A systematic review and meta-analysis. 2021 ASCO Annual Meeting, 2021. e-Pub 2021.
11. C. Xavier, F. Canedo, F. Lima, R. Melo, L.G. Lima, J.F. Marin, C. Souza, O. Feher. Complete Response to Alectinib Following Crizotinib in an ALK-Rearranged Metastatic Inflammatory Myofibroblastic Tumor. 2020 IALSC World Lung Conference, 2021. e-Pub 2021.
12. Mauricio Fernando Silva Almeida Ribeiro, Allan Andresson Lima Pereira, Camila Braganca Xavier, Mariana Scaranti, Luiza Dib, Tatiana Strava Correa, Marina Sahade Goncalves, David Queiroz Borges Muniz, Olavo Feher, Rodrigo Ramella Munhoz. Combined blockade of BRAF, MEK and PD-1/PD-L1 axis in comparison to dual BRAF/MEK inhibition for patients with advanced melanoma harboring BRAF mutations: a systematic review and meta-analysis. SBOC-AACR Joint Conference: A Translational Approach to Clinical Oncology.
13. Camila Braganca Xavier, Mohamed Alaa Gouda, Hung H. Le, Lei Kang, Milind Javle, Shubham Pant, Sarina A. Piha-Paul, Jordi Rodon Ahnert. Cholangiocarcinoma with gene fusions – navigating the genomic landscape and outcomes in a phase I unit. 6th Annual CCA Summit.
14. Xavier CB, Stephen B, Gurses S, Gocio MY, Kaseb M, Yang Y, Cimo AM, Derbala M, Tang T, Champiat S, Pohlmann PR, Mohamed Gouda MA, Tan HN, Martin CT, Ahnert JR, Yap TA, Dumbrava EE, Piha-Paul SA, Tsimberidou AM, Fu S, Hong DS, Meric-Bernstam F, Naing A. [Under embargo]. 2025 SITC Annual Meeting.
15. Yakimova D, Kravets A, Kudriavtseva K, Belousov D, Shaposhnikov K, Xavier CB, Zhao D, Pant S, Bagaev A, Hong D, Kotlov N, Rodon J. [Under embargo]. 2025 ESMO Congress.
16. FU S, Braganca Xavier C, Keyomarsi K, Wang Y, Ferry-Galow K, Wilsker D, Paradiso F, Kushnarev V, Yuan Y, Rebecca A Previs, Anthony D Elias, Richard Carvajal, Thomas J George, Yao S, Yuan Y, Ecaterina Ileana Dumbrava, Sarina A Piha-Paul, Tsimberidou AM, Jordi Rodon Ahnert, Westin S, Meric-Bernstam F. [Under embargo]. 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

Book Chapters

1. Beatriz Mendes Awni, Camila Braganca Xavier, Felipe Eduardo Martins de Andrade. COVID-19 and Breast Cancer. In: Comprehensive Clinical Oncology. Libromed Panama, 2023.
2. Camila Braganca Xavier. Precision Immunology. In: Precision Oncology Handbook. Wolters Kluwer.
3. Elena Fountzila, Camila Braganca Xavier, Apostolia Maria Tsimberidou. Targeted Therapy in Cancer. In: The MD Anderson Manual of Medical Oncology. McGraw Hill.

Web Publications

1. Camila Braganca Xavier. Navigating From Fellowship to Early Career in a Middle-Income Country: How To Manage Life-Work Balance.
2. Jessica Aduwo, Ivy Riano, Camila Braganca Xavier. Making the Most of the ASCO Annual Meeting at Every Career Stage: Tips for Students, Trainees, and Early-Career Oncologists.